B-type natriuretic peptide - TevaAlternative Names: Cardeva
Latest Information Update: 11 Aug 2011
At a glance
- Originator CoGenesys
- Mechanism of Action Diuretics
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Chronic heart failure
Most Recent Events
- 22 Feb 2008 CoGenesys has been acquired and merged into Teva Pharmaceutical Industries